D. Quiggle

发表

Endogenous natriuretic factors 7: biospecificity of a natriuretic gamma-tocopherol metabolite LLU-alpha.

D. Leipold, E. D. Murray, W. Wechter, 1997, The Journal of pharmacology and experimental therapeutics.

Endogenous Natriuretic Factors 7: Biospecificity of a Natriuretic (cid:103) -Tocopherol Metabolite LLU- (cid:97) 1

D. Leipold, E. D. Murray, W. Wechter, 1997 .

Antiproliferative Effects of the Enantiomers of Flurbiprofen

E. D. Murray, W. Wechter, J. Mccracken, 1996, Journal of clinical pharmacology.

Endogenous natriuretic factors. 5. Synthesis and biological activity of a natriuretic metabolite of diltiazem and its derivatives.

E. D. Murray, W. Wechter, D. Kantoci, 1996, Journal of medicinal chemistry.

Treatment and survival study in the C57BL/6J-APC(Min)/+(Min) mouse with R-flurbiprofen.

D. Leipold, W. Wechter, K. Gibson, 2000, Life sciences.

Bioinversion of R-flurbiprofen to S-flurbiprofen at various dose levels in rat, mouse, and monkey.

D. Leipold, E. D. Murray, W. Wechter, 2004, Chirality.

Mechanism of Enhancement of Intestinal Ulcerogenicity of S-Aryl Propionic Acids by Their R-Enantiomers in the Rat

Y. Mineyama, D. Leipold, E. D. Murray, 1998, Digestive Diseases and Sciences.

E-7869 (R-flurbiprofen) inhibits progression of prostate cancer in the TRAMP mouse.

N. Greenberg, D. Leipold, W. Wechter, 2000, Cancer research.

R-flurbiprofen chemoprevention and treatment of intestinal adenomas in the APC(Min)/+ mouse model: implications for prophylaxis and treatment of colon cancer.

D. Leipold, W. Wechter, K. Gibson, 1997, Cancer research.

The effects of R-flurbiprofen in reducing tumors in a multiple intestinal neoplasia mouse model

D. Quiggle, 2001 .